title: Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.
abstract: Phage therapy has been suggested as a potential treatment for highly antibiotic-resistant bacteria, such as the species of the Burkholderia cepacia complex (BCC). To address this hypothesis, experimental B. cenocepacia respiratory infections were established in mice using a nebulizer and a nose-only inhalation device. Following infection, the mice were treated with one of five B. cenocepacia-specific phages delivered as either an aerosol or intraperitoneal injection. The bacterial and phage titers within the lungs were assayed 2 days after treatment, and mice that received the aerosolized phage therapy demonstrated significant decreases in bacterial loads. Differences in phage activity were observed in vivo. Mice that received phage treatment by intraperitoneal injection did not demonstrate significantly reduced bacterial loads, although phage particles were isolated from their lung tissue. Based on these data, aerosol phage therapy appears to be an effective method for treating highly antibiotic-resistant bacterial respiratory infections, including those caused by BCC bacteria.
authors.affiliation: Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Diana D
authors.initials: DD
authors.lastname: Semler
authors.affiliation: Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Amanda D
authors.initials: AD
authors.lastname: Goudie
authors.affiliation: Department of Mechanical Engineering, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Warren H
authors.initials: WH
authors.lastname: Finlay
authors.affiliation: Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada jon.dennis@ualberta.ca.
authors.forename: Jonathan J
authors.initials: JJ
authors.lastname: Dennis
mesh_terms: D000336:Aerosols; D000818:Animals; D058491:Bacterial Load; D001435:Bacteriophages; D019121:Burkholderia Infections / Q000628:therapy*; D042602:Burkholderia cepacia complex; D024881:Drug Resistance, Bacterial; D005260:Female; D016867:Immunocompromised Host; D007274:Injections, Intraperitoneal; D008168:Lung / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D017900:Myoviridae; D012141:Respiratory Tract Infections / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000336:Aerosols